SCHEMBL7337144

SCHEMBL7337144

N#Cc1ccc2cc(Oc3ccccc3C=O)ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
GAA P10253 2/20 0.53
KMT2A Q03164 1/20 0.53
ALDH1A1 P00352 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPSR1 Q6W5P4 1/20 0.50
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
HTT P42858 2/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE4B Q07343 1/20 0.40
RCE1 Q9Y256 1/20 0.40
SLC6A4 P31645 2/20 0.39
AR P10275 3/20 0.38
F2 P00734 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764883 0.86 LMNA (0.66) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL31241185 0.83 LMNA (0.65) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL3144872 0.83 LMNA (0.65) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL28672124 0.79 LMNA (0.56) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL30185051 0.79 LMNA (0.56) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL5037397 0.78 LMNA (0.57) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL6296041 0.77 ALDH1A1 (0.43) LMNAGAAKMT2AALDH1A1HTT
SCHEMBL15778123 0.76 LMNA (0.51) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL31599176 0.76 LMNA (0.88) LMNAGAAKMT2AALDH1A1CYP1A2
SCHEMBL18570705 0.75 SCN8A (0.46) LMNAGAAKMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 LMNA 1886/4885GAA 193/4885KMT2A 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.